John J.V. McMurray
University of Glasgow
CardiologyHeart failureDiabetes mellitusMedicineEjection fraction
What is this?
Publications 1714
#1Pooja Dewan (Glas.: University of Glasgow)H-Index: 3
#2Scott D. Solomon (Brigham and Women's Hospital)H-Index: 107
Last. Marc S. Sabatine (Brigham and Women's Hospital)H-Index: 90
view all 25 authors...
AIMS The aim of this study was to examine whether left ventricular ejection fraction (LVEF) modified efficacy and safety of dapagliflozin 10 mg compared with placebo in the 4744 patients with LVEF ≤40% randomized in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF). METHODS AND RESULTS We examined whether LVEF, analysed categorically or continuously, modified the effect of dapagliflozin. The primary efficacy outcome was the composite of a worsening heart failu...
#1Stefan D. Anker (Charité)H-Index: 122
#2Javed Butler (UMMC: University of Mississippi Medical Center)H-Index: 37
Last. JohnGFCleland (Robertson Centre for Biostatistics)H-Index: 115
view all 34 authors...
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequently, for the trials themselves. Patients with heart failure may be at greater risk of infection with COVID-19 and the consequences might also be more serious, but they are also at risk of adverse outcomes if their clinical care is compromised. ...
1 CitationsSource
#1Silvio E. InzucchiH-Index: 75
#2Kieran F. DochertyH-Index: 4
Last. Michael BöhmH-Index: 119
view all 22 authors...
In DAPA-HF, the SGLT2 inhibitor (i) dapagliflozin (dapa) reduced worsening heart failure (HF) and cardiovascular death in 4744 patients (pts) with HF and reduced ejection fraction (HFrEF.) Only 45% had type 2 diabetes (T2D) at baseline. We evaluated whether dapa reduced the incidence of diabetes in the 55% of pts without T2D. Pts were randomized to dapa 10 mg or placebo and followed for a median of 18.2 months. New-onset T2D was defined as A1c ≥6.5% measured at 2 consecutive study visits post-ra...
#1Mona Fiuzat (Duke University)H-Index: 36
#2Naomi Lowy (FDA: Food and Drug Administration)H-Index: 1
Last. Mary Norine WalshH-Index: 39
view all 22 authors...
Highlights •HF patients experience a high burden of symptoms and functional limitations. •There remains an unmet need for new HF drugs, despite successful therapies that improve morbidity and mortality. •The majority of HF drugs in the United States are approved for reducing hospitalization and mortality, with only a few having an indication for improving quality of life, physical function, or symptoms. •Improvements in symptoms, physical function, or quality of life are potentially approvable e...
#1Peter C. ThomsonH-Index: 28
#2Patrick B. MarkH-Index: 27
Last. Ken Farrington (Lister Hospital)H-Index: 38
view all 17 authors...
#1Mark C. Petrie (Glas.: University of Glasgow)H-Index: 46
#2Pardeep S. Jhund (Glas.: University of Glasgow)H-Index: 36
Last. Sunil Bhandari (Hull Royal Infirmary)H-Index: 26
view all 17 authors...
#1Malgorzata WamilH-Index: 3
#2Ruth L. ColemanH-Index: 13
Last. Rury R. HolmanH-Index: 99
view all 5 authors...
Background and Aims: Insulin resistance (IR) is a possible mediator for development of heart failure (HF). We examined prospectively whether IR in people with newly-diagnosed type 2 diabetes (T2D) increased their risk of a composite endpoint of incident HF or all-cause mortality (ACM) (as death is a competing risk). Methods: UKPDS participants with Homeostasis Model Assessment v2 Insulin Resistance (HOMA2_IR) values (derived from paired fasting plasma glucose and insulin measures) were used in m...
#1João Pedro Ferreira (BHF: British Heart Foundation)
Last. John J.V. McMurray (BHF: British Heart Foundation)H-Index: 151
view all 9 authors...
Abstract Objectives The purpose of this study was to compare the win ratio (WR) with the corresponding hazard ratios (HRs) and 1/HR. Background The primary outcome in many cardiovascular trials is a composite that includes nonfatal and fatal events. The time-to-first event analysis gives equal statistical weighting to each component event. The WR, which takes into account the clinical importance and timing of the outcomes, has been suggested as an alternative approach. Methods Cox proportional h...
#1Pardeep S. Jhund (Glas.: University of Glasgow)H-Index: 36
#2Mark C. Petrie (Glas.: University of Glasgow)H-Index: 46
Last. Sunil Bhandari (Hull Royal Infirmary)H-Index: 26
view all 17 authors...
#1Kieran F. DochertyH-Index: 4
#2Silvio E. InzucchiH-Index: 75
Last. Marc S. SabatineH-Index: 90
view all 13 authors...